Literature DB >> 3001569

The opioid receptors in the hamster vas deferens are of the delta-type.

A T McKnight, A D Corbett, M Marcoli, H W Kosterlitz.   

Abstract

The motor responses of the isolated vas deferens of the hamster were unaffected by opioid-receptor agonists which are selective for the mu- or kappa-receptor, while agonists which show degrees of selectivity for the delta-opioid receptor caused dose-related inhibition of the stimulation-evoked contractions. The agonist action of the enkephalins and their congeners was only apparent when various inhibitors of tissue peptidases were present. Responses to opioid agonists were antagonised in a competitive manner by naloxone and by the selective delta-receptor antagonist, ICI 174864. It is noteworthy that the benzomorphans bremazocine, ethylketocyclazocine and Mr 2034, which are agonists at kappa-receptors in other tissues, are antagonists at the delta-receptor of the hamster vas deferens. Thus, the vas deferens of the hamster contains opioid receptors only of the delta-type and may therefore provide a simple and specific test for the assay of activity at the delta-opioid receptor.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3001569     DOI: 10.1016/0028-3908(85)90184-4

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  15 in total

1.  Pharmacological specificity of novel, synthetic, cyclic peptides as antagonists at tachykinin receptors.

Authors:  A T McKnight; J J Maguire; N J Elliott; A E Fletcher; A C Foster; R Tridgett; B J Williams; J Longmore; L L Iversen
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

2.  Inability of an opioid antagonist lacking negative intrinsic activity to induce opioid receptor up-regulation in vivo.

Authors:  B J Morris; M J Millan
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

3.  Enkephalins modulate inhibitory neuromuscular transmission in circular muscle of human colon via delta-opioid receptors.

Authors:  C H Hoyle; M A Kamm; G Burnstock; J E Lennard-Jones
Journal:  J Physiol       Date:  1990-12       Impact factor: 5.182

4.  Opioid activity of dermenkephalin analogues in the guinea-pig myenteric plexus and the hamster vas deferens.

Authors:  S Sagan; A D Corbett; M Amiche; A Delfour; P Nicolas; H W Kosterlitz
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

5.  The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.

Authors:  Pamela R Tsuruda; Ross G Vickery; Daniel D Long; Scott R Armstrong; David T Beattie
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-04       Impact factor: 3.000

6.  Pharmacological profile of various kappa-agonists at kappa-, mu- and delta-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the rat brain.

Authors:  A H Mulder; D M Burger; G Wardeh; F Hogenboom; A L Frankhuyzen
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

7.  Beta-endorphin-sensitive opioid receptors in the rat tail artery.

Authors:  P Illes; R Bettermann; I Brod; B Bucher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-04       Impact factor: 3.000

8.  Bremazocine is an agonist at kappa-opioid receptors and an antagonist at mu-opioid receptors in the guinea-pig myenteric plexus.

Authors:  A D Corbett; H W Kosterlitz
Journal:  Br J Pharmacol       Date:  1986-09       Impact factor: 8.739

9.  A method to estimate the potency of the mu-component of an opioid having mixed mu-, and kappa- and/or delta-agonist activities.

Authors:  X F Liu; X T Fan; K Kitamura; T Taniguchi; T Oka
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

10.  Guanine nucleotide-binding protein-coupled and -uncoupled states of opioid receptors and their relevance to the determination of subtypes.

Authors:  A Richardson; C Demoliou-Mason; E A Barnard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.